Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Pharm Res ; 10(4): 593-7, 1993 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-8483844

RESUMEN

The pharmacokinetics of AL03152 (RS) and its enantiomers, AL03802 (R) and AL03803 (S), were studied in the Sprague-Dawley rat following intravenous bolus administration. The enantiomers had differing pharmacokinetic profiles, while the racemic compound exhibited pharmacokinetic parameters approximating the mean values of the individual enantiomers. The total clearance (CLT) values of the two enantiomers were similar, but the intrinsic clearance (Cl(int)) was much greater for the S-enantiomer than for the R-enantiomer. The volume of distribution (Vss) for AL03802 (R) was threefold greater than that for AL03803 (S). The stereoselectivity in Vss could not be totally accounted for by the slight difference in serum protein binding of the isomers and resulted in a difference in the half-lives of the enantiomers. Only the R-isomer exhibited a persistent terminal elimination phase, consistent with more extensive tissue binding than the S-isomer. AL03152 enantiomers were equivalent in potency assessed from in vitro IC50 values toward rat lens aldose reductase and rat kidney L-hexonate dehydrogenase and lens EC50 values in diabetic rats.


Asunto(s)
Aldehído Reductasa/antagonistas & inhibidores , Fluorenos/farmacocinética , Hidantoínas/farmacocinética , Animales , Deshidrogenasas de Carbohidratos/antagonistas & inhibidores , Cromatografía de Gases , Fluorenos/administración & dosificación , Fluorenos/farmacología , Semivida , Hidantoínas/administración & dosificación , Hidantoínas/farmacología , Técnicas In Vitro , Inyecciones Intravenosas , Cristalino/efectos de los fármacos , Cristalino/metabolismo , Unión Proteica , Ratas , Ratas Sprague-Dawley , Sorbitol/metabolismo , Estereoisomerismo
2.
Xenobiotica ; 22(5): 543-50, 1992 May.
Artículo en Inglés | MEDLINE | ID: mdl-1413869

RESUMEN

1. Six potent aldose reductase inhibitors (ARI), three spirohydantoin (I to III) and three spirosuccinimide (IV to VI) compounds, showed similar IC50 activities in vitro for the inhibition of rat lens aldose reductase, but their ED50 values in diabetic rats varied as much as 20-fold in the lens and 50-fold in the sciatic nerve tissue. Pharmacokinetic studies were undertaken to investigate these findings. Structure-pharmacokinetic relationships were studied following i.v. administration to cynomolgus monkeys. 2. The clearance (CL) of each spirosuccinimide ARI was faster (greater than 5 times) than that of the corresponding spirohydantoin compound. In both series the CL values of the C(4) methyl and methoxy analogues were 4-fold greater than those for the unsubstituted compounds, although the CL values of the methoxy and methyl derivatives in the same series were not significantly different. 3. The volumes of distribution (Vss) of the spirohydantoins were about one-half those of the corresponding spirosuccinimides, and the Vss values of the parent compounds of both ARI series did not differ dramatically from those of their methyl and methoxy analogues. 4. All six compounds were eliminated from plasma in a biexponential fashion. The half-lives (lambda 1 and lambda 2) of the spirohydantoin compounds were much longer than those of the corresponding spirosuccinimide compounds, and the unsubstituted compounds had longer half-lives than their methyl and methoxy derivatives. The longest lambda 1 and lambda 2 half-lives were observed for imirestat, while two of the spirosuccinimides had the shortest half-lives. 5. These results indicate that the relationships observed between the in vitro and in vivo activities of the six ARI can be attributed to structurally dependent differences in metabolic clearance.


Asunto(s)
Aldehído Reductasa/antagonistas & inhibidores , Hidantoínas/farmacocinética , Compuestos de Espiro/farmacocinética , Succinimidas/farmacocinética , Administración Oral , Animales , Cristalinas/antagonistas & inhibidores , Diabetes Mellitus Experimental/enzimología , Diabetes Mellitus Experimental/metabolismo , Femenino , Fluorenos/farmacocinética , Fluorenos/farmacología , Hidantoínas/química , Hidantoínas/farmacología , Inyecciones Intravenosas , Ketamina/farmacología , Macaca fascicularis , Masculino , Estructura Molecular , Ratas , Ratas Sprague-Dawley , Compuestos de Espiro/química , Compuestos de Espiro/farmacología , Relación Estructura-Actividad , Succinimidas/química , Succinimidas/farmacología
3.
J Med Chem ; 34(11): 3229-34, 1991 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-1956041

RESUMEN

The first examples of spiro[fluorene-9,4'- and -9,5'-isothiazolidin]one dioxides (1 and 2) were synthesized and screened for activity as aldose reductase and L-hexonate dehydrogenase inhibitors. Compared to compounds 1, and 9,5'-compounds 2, synthesized from fluorene-9-sulfonamides by alkylation at C(9) with ethyl bromoacetate followed by cyclization, were more active, but relatively nonselective, inhibitors of aldose reductase and L-hexonate dehydrogenase, with IC50 values for in vitro inhibition of both enzymes on the order of 10(-7)-10(-8) M. However, the isomeric 9,4'-compounds 1, prepared by alkylation of fluorene-9-carboxylic acid esters with bromo- or iodomethanesulfonamide followed by cyclization, were more selective inhibitors of L-hexonate dehydrogenase with IC50 values of about 10(-6) M.


Asunto(s)
Aldehído Reductasa/antagonistas & inhibidores , Deshidrogenasas de Carbohidratos/antagonistas & inhibidores , Inhibidores Enzimáticos/síntesis química , Compuestos de Espiro/síntesis química , Tiazoles/síntesis química , Animales , Inhibidores Enzimáticos/farmacología , Ratas , Compuestos de Espiro/farmacología , Relación Estructura-Actividad , Tiazoles/farmacología
4.
Respir Care ; 27(7): 846-54, 1982 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-10315289

RESUMEN

Information handling is an important part of the activities of health care professionals, and the Parkland On-line Information System (POIS)--a computerized hospital information system--was established to more efficiently handle the processing and storage of information in our institution. Computerization of a respiratory therapy department is more effective if done in the context of a comprehensive, integrated hospital information system. Information and requests for services flow into the respiratory therapy departmental computer from other hospital terminals, and information, such as patient charges and statistical data, flow out of the departmental computer to those requesting such information. POIS is an implementation of the IBM Patient Care System. We have found that a computerized hospital information system can facilitate patient care by easing the burden of information processing.


Asunto(s)
Computadores , Departamentos de Hospitales/organización & administración , Sistemas en Línea/organización & administración , Servicio de Terapia Respiratoria en Hospital/organización & administración , Programas Informáticos , Hospitales con más de 500 Camas , Personal de Enfermería en Hospital , Texas
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA